Brief: LianBio Says BridgeBio Pharma Informed Co That Helsinn Healthcare Is Permanently Discontinuing Distribution Of Truseltiq

LianBio

12/10/2022 22:24

Oct 12 (Reuters) - BridgeBio Pharma Inc  BBIO.O :
    * LIANBIO -  BRIDGEBIO PHARMA INFORMED LIANBIO THAT HELSINN
HEALTHCARE IS PERMANENTLY DISCONTINUING DISTRIBUTION OF
TRUSELTIQ
    * LIANBIO -  BRIDGEBIO PHARMA INFORMED LIANBIO THAT IT
ANTICIPATES
REQUESTING WITHDRAWAL OF NDA IN UNITED STATES FOR TRUSELTIQ DUE
TO BUSINESS REASONS
    * LIANBIO - DUE TO PLANNED WITHDRAWAL OF NDA, BRIDGEBIO
INTENDS TO
CLOSE GLOBAL PHASE 3 PROOF-301 CLINICAL TRIAL OF INFIGRATINIB IN
FIRST-LINE CCA
    * LIANBIO - LIANBIO IS TERMINATING ACTIVITIES RELATED TO
PROOF-301
CLINICAL TRIAL IN CHINA OF INFIGRATINIB
    * LIANBIO - NO LONGER PLANS TO PURSUE DEVELOPMENT AND
COMMERCIALIZATION OF INFIGRATINIB IN CCA INDICATIONS IN ITS
LICENSED TERRITORIES
    * LIANBIO - INTENDS TO CONTINUE TO SUPPORT PATIENTS
CURRENTLY
BEING TREATED WITH INFIGRATINIB IN CHINA UNDER SPECIAL NAMED
PATIENT PROGRAM IN HAINAN
    * LIANBIO - EXPECTS TO CONTINUE PHASE 2A PROOF OF CONCEPT
CLINICAL
TRIAL OF INFIGRATINIB IN PATIENTS WITH LOCALLY ADVANCED OR
METASTATIC GASTRIC CANCER

Further company coverage:  BBIO.O 
 ((Reuters.Briefs@thomsonreuters.com;))